Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

A recent study has found that women with hypertension who take beta-blockers may face a higher risk of heart failure than men ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.